View Future GrowthSynthaverse 過去の業績過去 基準チェック /06Synthaverseの収益は年間平均-46.6%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間12.4% 7.4%割合で 増加しています。主要情報-46.63%収益成長率-46.53%EPS成長率Biotechs 業界の成長56.32%収益成長率7.36%株主資本利益率-18.97%ネット・マージン-54.52%次回の業績アップデート30 Sep 2026最近の業績更新Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025分析記事 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł254.8m market cap, or US$68.5m).New Risk • Oct 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł297.6m market cap, or US$80.9m).Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.New Risk • Sep 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł306.4m market cap, or US$84.5m).お知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025分析記事 • May 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...分析記事 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.お知らせ • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.分析記事 • Apr 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shareholders would be excited to see that the share price has had a great month, posting a...Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł5.07, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 55% over the past three years.分析記事 • Apr 18Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its ProblemsThe market shrugged off Synthaverse S.A.'s ( WSE:SVE ) weak earnings report. Despite the market responding positively...Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024Reported Earnings • Nov 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.お知らせ • Feb 03+ 2 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł5.70, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 487% over the past three years.Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 96% per year.分析記事 • Oct 14BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 09Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 36% share price gain to zł4.68, the stock trades at a trailing P/E ratio of 65.3x. Average trailing P/E is 26x in the Biotechs industry in Poland. Total returns to shareholders of 374% over the past three years.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł3.64, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 27% share price gain to zł3.58, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 28x in the Biotechs industry in Poland. Total returns to shareholders of 291% over the past three years.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to zł3.09, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł4.15, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total returns to shareholders of 342% over the past three years.Valuation Update With 7 Day Price Move • Dec 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł3.75, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 257% over the past three years.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 30% share price decline to zł4.91, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 52x in the Biotechs industry in Poland. Total returns to shareholders of 350% over the past three years.分析記事 • Nov 29More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) shareholders that were waiting for something to happen...分析記事 • Nov 16We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) EarningsBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s ( WSE:BML ) robust recent earnings didn't do much to move the...Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 02Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Is New 90 Day High Low • Mar 10New 90-day high: zł12.15The company is up 19% from its price of zł10.25 on 10 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.分析記事 • Mar 08Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jan 29What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) should be aware of the most powerful...分析記事 • Jan 03Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 49% over the past three months, it is easy to disregard BIOMED-LUBLIN Wytwórnia Surowic i...Is New 90 Day High Low • Dec 09New 90-day low: zł10.80The company is down 14% from its price of zł12.55 on 10 September 2020. The Polish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.分析記事 • Dec 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 131% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 08BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transactionBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced private placement of 6,000,000 series R shares on July 7, 2020. The company will issue shares of par value of PLN 0.1 per share without preemptive rights. The transaction has been resolved by the management of the company.収支内訳Synthaverse の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史WSE:SVE 収益、費用、利益 ( )PLN Millions日付収益収益G+A経費研究開発費31 Mar 2642-2339031 Dec 2542-2037030 Sep 2554-636030 Jun 2562136031 Mar 2571734031 Dec 2472832030 Sep 2463429030 Jun 2457228031 Mar 2461427031 Dec 2359525030 Sep 2353322030 Jun 2358720031 Mar 2354718031 Dec 2250617030 Sep 2251717030 Jun 2244416031 Mar 2244515031 Dec 2141415030 Sep 2139515030 Jun 2140515031 Mar 2135216031 Dec 2040416030 Sep 2041215030 Jun 2040315031 Mar 2040315031 Dec 1939215030 Sep 1935-2916030 Jun 1936-3117031 Mar 1935-3217031 Dec 1832-3216030 Sep 18311015030 Jun 18311116031 Mar 1830117031 Dec 1731118030 Sep 1731-2318030 Jun 1732-2720031 Mar 1737-2620031 Dec 1636-2620030 Sep 1646-4821030 Jun 1645-4518031 Mar 1647-3518031 Dec 1543-3717030 Sep 1538-2140質の高い収益: SVEは現在利益が出ていません。利益率の向上: SVEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SVEは利益が出ておらず、過去 5 年間で損失は年間46.6%の割合で増加しています。成長の加速: SVEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: SVEは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。株主資本利益率高いROE: SVEは現在利益が出ていないため、自己資本利益率 ( -18.97% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/29 23:16終値2026/07/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synthaverse S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025
分析記事 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...
Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.
Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Jun 04Synthaverse S.A., Annual General Meeting, Jun 29, 2026Synthaverse S.A., Annual General Meeting, Jun 29, 2026, at 12:00 Central European Standard Time.
New Risk • Mar 30New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł254.8m market cap, or US$68.5m).
New Risk • Oct 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł297.6m market cap, or US$80.9m).
Reported Earnings • Oct 06Second quarter 2025 earnings released: zł0.059 loss per share (vs zł0.02 profit in 2Q 2024)Second quarter 2025 results: zł0.059 loss per share (down from zł0.02 profit in 2Q 2024). Revenue: zł6.29m (down 59% from 2Q 2024). Net loss: zł4.77m (down 437% from profit in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
New Risk • Sep 22New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 36% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). High level of non-cash earnings (36% accrual ratio). Minor Risk Market cap is less than US$100m (zł306.4m market cap, or US$84.5m).
お知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025
分析記事 • May 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 26% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
分析記事 • Nov 28Synthaverse (WSE:SVE) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfSynthaverse S.A.'s ( WSE:SVE ) robust earnings report didn't manage to move the market for its stock. Our analysis...
Reported Earnings • Nov 21Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: zł13.4m (up 65% from 3Q 2023). Net loss: zł444.0k (loss narrowed 82% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 12% per year.
Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
お知らせ • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
分析記事 • Apr 20Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is LackingSynthaverse S.A. ( WSE:SVE ) shareholders would be excited to see that the share price has had a great month, posting a...
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł5.07, the stock trades at a trailing P/E ratio of 75.1x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 55% over the past three years.
分析記事 • Apr 18Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its ProblemsThe market shrugged off Synthaverse S.A.'s ( WSE:SVE ) weak earnings report. Despite the market responding positively...
Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024
Reported Earnings • Nov 26Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.
Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.
お知らせ • Feb 03+ 2 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to zł5.70, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 487% over the past three years.
Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 99% per year whereas the company’s share price has increased by 96% per year.
分析記事 • Oct 14BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite SensiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 09Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 36% share price gain to zł4.68, the stock trades at a trailing P/E ratio of 65.3x. Average trailing P/E is 26x in the Biotechs industry in Poland. Total returns to shareholders of 374% over the past three years.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł3.64, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 25x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.
Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 130% per year but the company’s share price has only increased by 62% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 27% share price gain to zł3.58, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 28x in the Biotechs industry in Poland. Total returns to shareholders of 291% over the past three years.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to zł3.09, the stock trades at a trailing P/E ratio of 41.8x. Average trailing P/E is 33x in the Biotechs industry in Poland. Total returns to shareholders of 268% over the past three years.
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł4.15, the stock trades at a trailing P/E ratio of 56.2x. Average trailing P/E is 48x in the Biotechs industry in Poland. Total returns to shareholders of 342% over the past three years.
Valuation Update With 7 Day Price Move • Dec 27Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł3.75, the stock trades at a trailing P/E ratio of 50.8x. Average trailing P/E is 49x in the Biotechs industry in Poland. Total returns to shareholders of 257% over the past three years.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment deteriorated over the past weekAfter last week's 30% share price decline to zł4.91, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 52x in the Biotechs industry in Poland. Total returns to shareholders of 350% over the past three years.
分析記事 • Nov 29More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) shareholders that were waiting for something to happen...
分析記事 • Nov 16We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) EarningsBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s ( WSE:BML ) robust recent earnings didn't do much to move the...
Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 02Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Is New 90 Day High Low • Mar 10New 90-day high: zł12.15The company is up 19% from its price of zł10.25 on 10 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.
分析記事 • Mar 08Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jan 29What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?Every investor in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. ( WSE:BML ) should be aware of the most powerful...
分析記事 • Jan 03Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?With its stock down 49% over the past three months, it is easy to disregard BIOMED-LUBLIN Wytwórnia Surowic i...
Is New 90 Day High Low • Dec 09New 90-day low: zł10.80The company is down 14% from its price of zł12.55 on 10 September 2020. The Polish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period.
分析記事 • Dec 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 131% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 08BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced a financing transactionBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced private placement of 6,000,000 series R shares on July 7, 2020. The company will issue shares of par value of PLN 0.1 per share without preemptive rights. The transaction has been resolved by the management of the company.